The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ieshir Jaju
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ieshir Jaju, a promoter of Godavari Drugs Limited, acquired 2,00,000 convertible warrants through a preferential issue on 18th March 2026. These warrants represent 1.60% of the company's total share/voting capital. Following this acquisition, the company's total equity share capital increased from Rs. 7.53 crore (75.30 lakh shares) to Rs. 10.13 crore (1.01 crore shares), and the total diluted share capital stands at Rs. 12.49 crore (1.25 crore shares). The disclosure was filed under Regulation 29(2) of SEBI Takeover Regulations on 20th March 2026.
This is a positive signal indicating promoter confidence and commitment to the company. Increasing promoter holding through warrants strengthens the promoter's stake and aligns their interests with minority shareholders, though it also results in equity dilution upon conversion.